Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma.

Q1 Medicine
CNS Oncology Pub Date : 2018-07-01 Epub Date: 2018-04-09 DOI:10.2217/cns-2017-0039
Andrea Wasilewski, Nimish Mohile
{"title":"Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma.","authors":"Andrea Wasilewski,&nbsp;Nimish Mohile","doi":"10.2217/cns-2017-0039","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adult pilocytic astrocytomas are rare and highly vascular tumors.</p><p><strong>Aim: </strong>We hypothesized that they may be uniquely responsive to bevacizumab (BEV).</p><p><strong>Patients: </strong>We present four adult patients with pathologically diagnosed WHO grade I pilocytic astrocytoma who had robust and durable responses to BEV at time of recurrence. Three patients developed radiographic changes on MRI, consistent with progressive disease based on response assessment in neuro-oncology criteria. Median time to recurrence was 8.5 months.</p><p><strong>Methods: </strong>All patients were treated with six cycles of BEV for recurrence.</p><p><strong>Results: </strong>At the end of treatment, all patients had achieved a clinical and radiographic response. Median follow-up time after BEV is 20.5 months.</p><p><strong>Conclusion: </strong>This suggests that BEV may have true antitumor activity in adult pilocytic astrocytomas and may be important for achieving durable disease control.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2017-0039","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2017-0039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/4/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 9

Abstract

Background: Adult pilocytic astrocytomas are rare and highly vascular tumors.

Aim: We hypothesized that they may be uniquely responsive to bevacizumab (BEV).

Patients: We present four adult patients with pathologically diagnosed WHO grade I pilocytic astrocytoma who had robust and durable responses to BEV at time of recurrence. Three patients developed radiographic changes on MRI, consistent with progressive disease based on response assessment in neuro-oncology criteria. Median time to recurrence was 8.5 months.

Methods: All patients were treated with six cycles of BEV for recurrence.

Results: At the end of treatment, all patients had achieved a clinical and radiographic response. Median follow-up time after BEV is 20.5 months.

Conclusion: This suggests that BEV may have true antitumor activity in adult pilocytic astrocytomas and may be important for achieving durable disease control.

Abstract Image

成人复发性毛细胞星形细胞瘤对贝伐单抗的持久反应。
背景:成人毛细胞星形细胞瘤是一种罕见的高血管性肿瘤。目的:我们假设它们可能对贝伐单抗(BEV)有独特的反应。患者:我们报告了4例经病理诊断为WHO I级毛细胞星形细胞瘤的成年患者,他们在复发时对BEV有强烈而持久的反应。3例患者在MRI上出现影像学改变,根据神经肿瘤学标准的反应评估,这与疾病的进展一致。中位复发时间为8.5个月。方法:所有患者均接受6个周期的BEV治疗。结果:治疗结束时,所有患者均获得临床和影像学反应。BEV术后中位随访时间为20.5个月。结论:BEV在成人毛细胞星形细胞瘤中可能具有真正的抗肿瘤活性,可能对实现疾病的持久控制具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CNS Oncology
CNS Oncology Medicine-Neurology (clinical)
CiteScore
3.80
自引率
0.00%
发文量
12
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信